Concepedia

Hendrik-Tobias Arkenau

HA

Statistics

Publications

12

Citations

2.4K

H-Index

12

Active since

2008

Affiliations

Sarah Cannon Research Institute(Current)

University College London

Institut Gustave Roussy

Royal Marsden NHS Foundation Trust

Peter MacCallum Cancer Centre

Hendrik-Tobias Arkenau is an author at Sarah Cannon Research Institute specializing in oncology, medicine, and pharmacology.

Publications per year

2008–2021

12

Publications

12

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Thomas Powles, Peter H. O’Donnell, Christophe Massard et al. · JAMA Oncology · 2017 · 846 citations

, , +17

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero, Axel Grothey, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2021 · 544 citations · Full text

, , +16

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

Manish A. Shah, Takashi Kojima, Daniel Hochhauser et al. · JAMA Oncology · 2018 · 519 citations · Full text

, , +17

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer

Toni K. Choueiri, Elizabeth R. Plimack, Hendrik-Tobias Arkenau et al. · Journal of Clinical Oncology · 2017 · 175 citations · Full text

, , +17

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

Joaquı́n Mateo, Gopinath Ganji, Charlotte Lemech et al. · Clinical Cancer Research · 2017 · 143 citations · Full text

, , +17

1–5 of 12